|
SEQ_NO
|
1
|
Date of announcement
|
2022/12/20
|
Time of announcement
|
17:10:00
|
|
Subject
|
Announcement that Microbio (Shanghai) and Oneness signed an agreement
with Cho Pharma to jointly develop glycosylation-based nucleic acid delivery technology.
|
||||
|
Date of events
|
2022/12/20
|
To which item it meets
|
paragraph 53
|
||
|
Statement
|
1.Date of occurrence of the event:2022/12/20
2.Company name:Microbio (Shanghai)
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):subsidiary
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
(1) Small nucleic acid medicines (eg. siRNA) have become the focus of global
new drug development, and drug delivery technology is the most important
key to the development of nucleic acid medicines. At present, the only
successful technology is a nature sugar molecule called
N-acetylgalactosamine (GalNAc) that are capable to deliver the medicine
to the liver effectively. GalNAc is a prove that sugar molecules can be
used as a key carrier for nucleic acid delivery. In addition to the
liver, delivery technologies to other organs are urgently needed.
(2) Microbio (Shanghai) and Oneness will join hands with Cho Pharma, an
expert company of molecular glycosylation, to focus on development of
glycosylation-based nucleic acid delivery technology, to develop globally
competitive nucleic acid medicines that can target to specific organs and
achieve precision therapy.
6.Countermeasures:None
7.Any other matters that need to be specified:None
|
||||
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.